These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 949459)

  • 1. Regression of a hamster melanoma with intralesional Corynebacterium granulosum.
    Paslin D
    Br J Dermatol; 1976 Jun; 94(6):639-44. PubMed ID: 949459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of a transplantable hamster melanoma by intralesional injections of Corynebacterium granulosum.
    Paslin D; Dimitrov NV; Heaton C
    J Natl Cancer Inst; 1974 Feb; 52(2):571-3. PubMed ID: 4593141
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative effect of anaerobic coryneforms on a murine melanoma.
    Paslin DA
    Cancer; 1977 Jun; 39(6):2405-10. PubMed ID: 872039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antitumour activity of maltose tetrapalmitate compared with other immunoadjuvants, and its effectiveness after tumour surgery.
    El Kappany H; Chopra C; Nigam VN; Brailovsky CA; Elhilali M
    Br J Cancer; 1980 Nov; 42(5):703-11. PubMed ID: 7459208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of BCG and C. parvum treatment on human melanoma xenografts.
    Garrett AJ; Reeson DE; Osborn TW; Boulger LR
    Dev Biol Stand; 1977 Apr 13-15; 38():363-8. PubMed ID: 608525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of solid tumours by intratumoral injection of immunostimulants].
    Salomon JC; Lynch N
    Ann Immunol (Paris); 1977; 128(1-2):125-7. PubMed ID: 322574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
    Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
    J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery plus Corynebacterium parvum immunotherapy for Lewis lung carcinoma in mice.
    Karrer K; Rella W; Goldin A
    Eur J Cancer (1965); 1979 Jun; 15(6):867-73. PubMed ID: 499275
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy of cutaneous malignant melanoma: a critical review.
    Koh HK; Sober AJ; Harmon DC; Lew RA; Carey RW
    Med Pediatr Oncol; 1985; 13(5):244-60. PubMed ID: 3897817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy.
    Parodi AL; Misdorp W; Mialot JP; Mialot M; Hart AA; Hurtrel M; Salomon JC
    Cancer Immunol Immunother; 1983; 15(3):172-7. PubMed ID: 6555059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoprophylaxis and immunotherapy for a murine fibrosarcoma with C. granulosum and C. parvum.
    Milas L; Gutterman JU; Basic I; Hunter N; Mavligit GM; Hersh EM; Withers HR
    Int J Cancer; 1974 Oct; 14(4):493-503. PubMed ID: 4459276
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Corynebacterium parvum on tumour metastases in mice.
    Castro JE
    Br J Surg; 1977 Oct; 64(10):721-4. PubMed ID: 922293
    [No Abstract]   [Full Text] [Related]  

  • 15. The influence of nonspecific immunotherapy on the course of murine melanoma.
    Woods JE; Ritts RE
    J Surg Oncol; 1977; 9(1):15-20. PubMed ID: 839793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
    Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
    Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corynebacterium parvum as a therapeutic antitumor agent in mice. II. Local injection.
    Scott MT
    J Natl Cancer Inst; 1974 Sep; 53(3):861-5. PubMed ID: 4213016
    [No Abstract]   [Full Text] [Related]  

  • 18. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
    Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
    Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metastasis in mice bearing experimental intraocular melanoma and inhibition of its metastasis with BCG].
    Yokoyama T
    Nippon Ganka Gakkai Zasshi; 1985 Sep; 89(9):1064-8. PubMed ID: 4083192
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.